Pharmacokinetics and urinary excretion of DMXBA (GTS-21), a compound enhancing cognition.

@article{Mahnir1998PharmacokineticsAU,
  title={Pharmacokinetics and urinary excretion of DMXBA (GTS-21), a compound enhancing cognition.},
  author={V Mahnir and Bing Lin and Katalin Prokai-Tatrai and William R. Kem},
  journal={Biopharmaceutics & drug disposition},
  year={1998},
  volume={19 3},
  pages={147-51}
}
DMXBA (3-(2,4-dimethoxybenzylidene)-anabaseine, also known as GTS-21) is currently being tested as a possible pharmacological treatment of cognitive dysfunction in Alzheimer's disease. In this study, plasma and brain pharmacokinetics as well as urinary excretion of this compound have been evaluated in adult rats. DMXBA concentrations were determined by HPLC. Following a 5 mg kg-1 iv dose, DMXBA plasma concentration declined bi-exponentially with mean (+/- SE) absorption and elimination half… CONTINUE READING